Cardiac gene editing holds promising potential in revolutionizing the landscape of cardiovascular medicine. This innovative field involves precisely modifying the genetic code within cardiac cells to address and rectify underlying genetic factors contributing to heart diseases. By leveraging advanced molecular tools such as CRISPR-Cas9, researchers aim to target specific genes associated with cardiac conditions, paving the way for personalized therapeutic interventions. The ability to edit genes directly in cardiac tissue opens new avenues for treating congenital heart disorders, genetic predispositions, and other cardiovascular ailments. While still in the early stages of development, cardiac gene editing represents a cutting-edge approach that holds great promise for advancing our understanding of cardiac health and fostering breakthroughs in tailored treatments for individuals with various cardiovascular conditions.
Title : Surgical fetal stem cells implantation in heart failure patients long term results at 14 years
Federico Benetti, Benetti Foundation, Argentina
Title : Exploring new biomarkers of cardiomyopathy
Shuping Zhong, University of Southern California, United States
Title : The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF
Thomas Bernd Dschietzig, Relaxera GmbH & Co. KG, Germany
Title : Cancer and cardiovascular diseases: Common pathogenesis mechanisms and risk factors
Mekhman N Mamedov, National Research Center for Preventive Medicine, Russian Federation
Title : Pulse field ablation for atrial fibrillation complications: What do we know yet
Narendra Kumar, HeartbeatsZ Academy, United Kingdom
Title : Lipoprotein (a): The hidden cardiovascular risk
Syed Raza, Awali Hospital, Bahrain